This study highlights differences in drug prescription and purchase patterns in five sub-Saharan African countries.
artemisinin-based combination therapy (ACT)
Individuals/caregivers were more likely to believe that the illness was malaria when the patient was treated with ACT, regardless of their test result.
Apart from k13, pfarps10, pffd and pfmdr2 are also useful for molecular surveillance of artemisinin resistance especially where k13 mutation has not been reported.
Mass drug administration for malaria was well accepted by communities at high risk of malaria in Zanzibar, with high participation and completion rates.
Training teachers to test for and treat uncomplicated malaria in schools was well received by both users and implementers alike, and was perceived by the majority of stakeholders to be a valuable programme.
Based on the available evidence, this study demonstrated the superiority of DHAP among currently recommended artemisinin-based combinations. The
The spread of artemisinin and partner drug resistance through Asia requires changes in first-line therapy.
Addressing the availability and distribution of non-QAACT will require effective private sector engagement and evidence-based strategies to address provider and consumer demand for these products.
As new infections can be prevented by a long acting partner drug to the artemisinins, DHAPQ should be preferred in places as Nchelenge district where transmission is intense while in areas of low transmission intensity AL or MQAS may be used.
The ACTwatch data has shown the importance of the private sector in terms of access to malaria treatment for the majority of the population in Benin.